Pulmonx Corporation (LUNG) Earnings Call Analysis
NASDAQ · Healthcare · Medical Devices
Earnings Reports
-
Pulmonx (LUNG) Q2 2026: Cash Flow Break-Even Path Secured by Expanded Debt Facility
July 30, 2026
-
Pulmonx (LUNG) Q1 2026: U.S. Treating Centers Expand by 15 as Sales Force Rebuild Drives Transition Year
April 30, 2026
-
Pulmonx (LUNG) Q4 2025: Operating Expenses Cut 10% as U.S. Sales Force Rebuilds for Back-Half Rebound
March 05, 2026
-
Pulmonx (LUNG) Q3 2025: U.S. Revenue Growth Slows to 1% as Leadership Signals Cost Discipline
November 13, 2025
-
Pulmonx (LUNG) Q2 2025: International Revenue Jumps 32% as U.S. Ramp Lags Guidance Reset
July 30, 2025
-
Palmonix (LUNG) Q1 2025: International Revenue Surges 39% as U.S. Initiatives Target Growth Reacceleration
July 04, 2025